Pfizer Inc. $PFE Shares Sold by WBH Advisory Inc.

WBH Advisory Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 9.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 17,130 shares of the biopharmaceutical company’s stock after selling 1,809 shares during the quarter. WBH Advisory Inc.’s holdings in Pfizer were worth $415,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer in the first quarter worth about $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Trading Up 0.7%

NYSE:PFE opened at $24.68 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.22. The firm has a market cap of $140.33 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average is $24.89 and its 200-day moving average is $24.12.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.